Evidence map›Paper›PMID 41341524›Full record

ArticleJournal of machine learning research : JMLR2025

Efficient and Robust Semi-supervised Estimation of Average Treatment Effect with Partially Annotated Treatment and Response.

Jue Hou, Rajarshi Mukherjee, Tianxi Cai

Abstract read
In one paragraph

Article in Journal of machine learning research : JMLR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jue HouDivision of Biostatistics, University of Minnesota School of Public Health, Minneapolis, MN 55455, USA.
Rajarshi MukherjeeDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02120, USA.
Tianxi CaiDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02120, USA.

Funding

Statistical Methods for Optimizing Personalized Treatment SelectionR01HL089778 · NHLBI · STANFORD UNIVERSITY · PI LU TIAN · 2008 to 2026
$4.8M
Bridging clinical trial and real-world data via machine learning to advance rheumatoid arthritis treatment strategiesR01AR080193 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI CAI, TIANXI, LIAO, KATHERINE PHOENIX · 2022 to 2025
$2.7M
Semi-supervised Approaches to Denoising Electronic Health Records Data for Risk PredictionR01LM013614 · NLM · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI CAI, TIANXI, GUO, ZIJIAN · 2021 to 2024
$1.4M
FDA HHS U01 FD007929NHLBI NIH HHS R01 HL089778NIAMS NIH HHS R01 AR080193NLM NIH HHS R01 LM013614
6 · The paper itself

Abstract

A notable challenge of leveraging Electronic Health Records (EHR) for treatment effect assessment is the lack of precise information on important clinical variables, including the treatment received and the response. Both treatment information and response cannot be accurately captured by readily available EHR features in many studies and require labor-intensive manual chart review to precisely annotate, which limits the number of available gold standard labels on these key variables. We considered average treatment effect (ATE) estimation when 1) exact treatment and outcome variables are only observed together in a small labeled subset and 2) noisy surrogates of treatment and outcome, such as relevant prescription and diagnosis codes, along with potential confounders are observed for all subjects. We derived the efficient influence function for ATE and used it to construct a semi-supervised multiple machine learning (SMMAL) estimator. We justified that our SMMAL ATE estimator is semi-parametric efficient with B-spline regression under low-dimensional smooth models. We developed the adaptive sparsity/model doubly robust estimation under high-dimensional logistic propensity score and outcome regression models. Results from simulation studies demonstrated the validity of our SMMAL method and its superiority over supervised and unsupervised benchmarks. We applied SMMAL to the assessment of targeted therapies for metastatic colorectal cancer in comparison to chemotherapy.

Indexed as

double robustnesshigh-dimensional regressionsemi-parametric efficiencysemi-supervised learning

Identifiers

PMID41341524
PMCPMC12671556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.